Lower Levels of Fat Hormone Adiponectin Can Cause Sepsis
According to the Centers of Disease Control and Prevention, sepsis comes second in the leading causes of death in the United States in intensive care patients suffering from non-heart related ailments. It stands tenth in the list of most-common causes of deaths in the country.
Sepsis is typically diagnosed as a widespread inflammation with the presence of infection. Patients with a lowered immune system are an increased risk. When adiponection (a protein hormone) levels are low, which is typical in obesity, there is a reduction of anti-inflammatory effects on the cells lining the walls of blood vessels.
Canadian researchers at St. Michael’s Hospital and the University of Toronto found that lower levels of the fat hormone adiponectin can increase the risk of sepsis related deaths. The results of their findings were presented at the October 2009 Clinical Congress of the American College of Surgeons held in Chicago.
What Research Uncovered About Lower Fat Hormone Adiponectin Levels and Sepsis Nexus?
- Presence of bacteria and infectious organisms in the blood leads to a life threatening inflammation.
- People with a weak immune system or in a critically ill state are at higher risks of developing this condition.
- In people suffering from metabolic syndrome, the risks of losing life after surgery is two to three times more when compared to normal people.
- Reduced adiponectin levels are observed in patients with obesity and diabetes and may link adiposity to adverse cardiovascular outcomes.
- The results of this study made the researchers believe that lower levels of this hormone might predispose metabolic syndrome patients to develop sepsis and its related complications.
- When the levels of this hormone were restored back to normalcy, the risk of blood infection also reduced in experimental mice.
Significance of the Research on Lower Fat Hormone Adiponectin Levels and Sepsis Nexus:
According to the researchers, their study had two pronged implications. Firstly, low levels of adiponectin can predict risk of sepsis-related inflammation. Secondly, it opens up the possibilities for developing novel ways of treatment by increasing the levels of this hormone in the body of obese patients.
Further research is focused on carrying out a small clinical trial where the success of the research will now be repeated on humans. If the results turn out to be safe and positive, a large scale trial can be initiated.